Israel - Hebrew - Ministry of Health

unipharm trading ltd, israel - trastuzumab - trastuzumab 420 mg/vial - trastuzumab

Israel - Hebrew - Ministry of Health

unipharm trading ltd, israel - pegfilgrastim - תמיסה להזרקה - pegfilgrastim 10 mg/ml - pegfilgrastim

Israel - Hebrew - Ministry of Health

pfizer pharmaceuticals israel ltd - tafamidis - קפסולות ג'לטין רכות - tafamidis 61 mg - tafamidis

Israel - Hebrew - Ministry of Health

david margalit & co.ltd - metoclopramide hydrochloride - תמיסה להזרקה - metoclopramide hydrochloride 5 mg/ml - metoclopramide

Israel - Hebrew - Ministry of Health

pfizer pharmaceuticals israel ltd - taliglucerase alfa - אבקה להכנת תמיסה לאינפוזיה - taliglucerase alfa 200 u/vial - taliglucerase alfa - taliglucerase alfa - elelyso (taliglucerase alfa ) for injection is a hydrolytic lysosomal glucocerebroside - specific enzyme indicated for long - term enzyme replacement therapy (ert) for adults with a confirmed diagnosis of type 1 gaucher disease.

Israel - Hebrew - Ministry of Health

sanofi israel ltd - enoxaparin sodium - תמיסה להזרקה - enoxaparin sodium 100 mg/ml ml - enoxaparin - enoxaparin - enoxaparin sodium is an anti-coagulant. at dosesof 20 mg and 40 mg it is indicated for: - prophylactic treatment of thrombo-embolic disorders of venous origin and in particular in orthopedic surgery or in general surgery. - prevention of thrombus formation in the extra-corporeal circulation during hemodialysis. at dosege of 40 mg the indications are: - prophylactic treatment of deep vein thrombosis in patients who are bedridden due to an acute medial disorder: - heart failure (hyha class iii or iv) - acute respiratory failure - episode of acute infection or acute rheumatic disorder combined with at least one other venous thromboembolic risk factor. at high doses of 60, 80 ,100 mg clexan is indicated for: -treatment of deep vein thrombosis (dvt). - treatment of unstable angina and non-q-wave myocardial infaction administered concurrently with aspirin. - treatment of pulmonary embolism.treatment of acute st- segment elevation myocardial infarction, in combination with a thrombolytic agent in patients eligible o

Israel - Hebrew - Ministry of Health

novartis israel ltd - hydrochlorothiazide; valsartan - טבליות מצופות פילם - valsartan 80 mg; hydrochlorothiazide 12.5 mg - valsartan and diuretics - valsartan and diuretics - co-diovan is indicated for the treatment of hypertension for patients in whom combination therapy is appropriate.

Israel - Hebrew - Ministry of Health

novartis israel ltd - hydrochlorothiazide; valsartan - טבליות מצופות פילם - valsartan 160 mg; hydrochlorothiazide 12.5 mg - valsartan and diuretics - valsartan and diuretics - co-diovan is indicated for the treatment of hypertension in patients whose blood pressure is not adequately controlled by monotherapy. this fixed combination should be used as second-line therapy.

Israel - Hebrew - Ministry of Health

novartis israel ltd - hydrochlorothiazide; valsartan - טבליות מצופות פילם - valsartan 160 mg; hydrochlorothiazide 25 mg - valsartan and diuretics - valsartan and diuretics - co-diovan is indicated for the treatment of hypertension in patients whose blood pressure is not adequately controlled by monotherapy. this fixed combination should be used as second-line therapy.

Israel - Hebrew - Ministry of Health

novartis israel ltd - amoxicillin as trihydrate; clavulanic acid as potassium - אבקה להכנת תרחיף - amoxicillin as trihydrate 400 mg / 5 ml; clavulanic acid as potassium 57 mg / 5 ml - amoxicillin - amoxicillin - for the treatment of lower respiratory tract infections, otitis media infections, sinusitis infections, acute pharyngitis, skin and soft tissues infections and urinary tract infections caused by beta-lactamase producing organisms which are susceptible to amoxycillin + potassium clavulanate and are resistant to other beta-lactam antibiotics.